Research article · 15 Apr 2026
Conference abstractPublished 26 Jun 2014
Biological basis for rational use of erythropoietin stimulating agents
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
E rythropoietin stimulating agents have been instrumental in improving the lives of patients on dialysis, decreasing transfusions, and reducing sensitization. However over the past 10 years, there have been a number of large clinical trials such as TREAT, CHOIR, and the Normal Hematocrit Study demonstrating that targeting a higher hematocrit leads to worse outcomes. In addition, trials have demonstrated that higher doses of erythropoietin lead to a higher recurrence of cancers. What has been lacking is a biologic basis for these untoward results. There are two known receptors for erythropoietin, the homodimeric erythropoietin receptor, responsible for erythropoiesis, and the more ubiquitous heterodimeric erythropoietin receptor consisting of an erythropoietin receptor and the beta-common receptor. These receptors have different Km?s with the Km of the heterodimeric erythropoietin receptor/beta-common receptor being ten-fold higher than the homodimeric erythropoietin receptor. Thus, targeting a higher hemoglobin with larger doses of erythropoietin stimulating agent increases the likelihood of stimulation of the heterodimeric erythropoietin receptor/beta-common receptor. Our work has demonstrated that stimulating the heterodimeric erythropoietin receptor/beta-common receptor can explain all of the untoward events seen in the clinical trials. Thus understand the biology of both erythropoietin receptors leads to a rational set of guidelines for use of erythropoietin stimulating agents and a rational set of guidelines to predict the safety profile of the novel agents to stimulate erythropoiesis
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Mark S Segal”
